Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

394 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.
Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, Svarovskaia E, Dvory-Sobol H, Doehle B, Hedskog C, Yun C, Brainard DM, Knox S, McHutchison JG, Miller MD, Mo H, Chuang WL, Jacobson I, Dore GJ, Sulkowski M. Zeuzem S, et al. Among authors: mchutchison jg. J Hepatol. 2017 May;66(5):910-918. doi: 10.1016/j.jhep.2017.01.007. Epub 2017 Jan 18. J Hepatol. 2017. PMID: 28108232 Free article.
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR. Zeuzem S, et al. Among authors: mchutchison jg. Hepatology. 2012 Mar;55(3):749-58. doi: 10.1002/hep.24744. Hepatology. 2012. PMID: 22006408 Clinical Trial.
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection.
Wyles DL, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, Massetto B, Kanwar B, Trenkle JD, Pang PS, Zhu Y, Mo H, Brainard DM, Subramanian GM, McHutchison JG, Habersetzer F, Sulkowski MS. Wyles DL, et al. Among authors: mchutchison jg. Hepatology. 2014 Jul;60(1):56-64. doi: 10.1002/hep.27053. Epub 2014 May 28. Hepatology. 2014. PMID: 24501005 Clinical Trial.
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.
Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, Ouyang W, Han B, Xu S, Ku K, Chiu S, Gane E, Jacobson IM, Nelson DR, Lawitz E, Wyles DL, Bekele N, Brainard D, Symonds WT, McHutchison JG, Miller MD, Mo H. Svarovskaia ES, et al. Among authors: mchutchison jg. Clin Infect Dis. 2014 Dec 15;59(12):1666-74. doi: 10.1093/cid/ciu697. Epub 2014 Sep 28. Clin Infect Dis. 2014. PMID: 25266287 Free PMC article. Clinical Trial.
Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry.
Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, Riad J, Mikhail S, Kersey K, Jiang D, Massetto B, Doehle B, Kirby BJ, Knox SJ, McHutchison JG, Symonds WT. Ruane PJ, et al. Among authors: mchutchison jg. J Hepatol. 2015 May;62(5):1040-6. doi: 10.1016/j.jhep.2014.10.044. Epub 2014 Nov 5. J Hepatol. 2015. PMID: 25450208 Free article. Clinical Trial.
394 results